Skip to content

Retinal Imaging in Patients With Inherited Retinal Degenerations

High Resolution Retinal Imaging in Patients With Inherited Retinal Degenerations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00254605
Enrollment
400
Registered
2005-11-16
Start date
2005-11-01
Completion date
2028-11-01
Last updated
2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis Pigmentosa

Keywords

imaging, adaptive optics scanning laser ophthalmoscope, optical coherence tomography, electroretinography

Brief summary

The purpose of this study is to determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO).

Detailed description

Retinal degenerations are a group of inherited diseases that result in progressive death of the vision cells, or photoreceptors. Currently there is no treatment or cure for any of these diseases and they ultimately cause blindness in affected patients. We propose to investigate the structure and function of the human retina in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO). We will correlate the images of retinal structure produced by the AOSLO with Optical Coherence Tomography (OCT) images of the retina. In addition, we will study the vision of individual photoreceptors using the AOSLO to perform a novel technique, microperimetry, in patients with retinal degenerations. We will compare the results of microperimetry with standard measures of vision used in Ophthalmology clinics, including visual acuity, automated perimetry, fundus photography and multifocal electroretinography (mfERG). The results of this work will provide insight into the mechanism of vision loss among patients with diverse retinal disorders. Specifically, we will study cone structure and function in patients with retinal degenerations with different etiologies: retinitis pigmentosa, a disease usually caused by rod-specific mutations; cone-rod dystrophy, which primarily affects cones rather than rods; and Best's disease, a disease caused by a defect in the retinal pigment epithelium (RPE). In addition, we will study the effect that lipofuscin, a byproduct of photoreceptor metabolism that accumulates in the RPE in diseases such as Stargardt's disease, Best's disease and age-related macular degeneration (AMD), has on cone structure and function, with the goal of understanding how these diseases cause blindness. Better understanding of the mechanisms of vision loss in patients with retinal degeneration should ultimately lead to treatments for these blinding conditions.

Interventions

None listed

Sponsors

University of California, San Francisco
Lead SponsorOTHER
University of California, Berkeley
CollaboratorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects must speak and understand English * Subjects must have pupils that dilate to at least 6 millimeters diameter. * Subjects must be willing to travel to University of California (UC) Berkeley. * Subjects are financially responsible for their travel to the San Francisco area if they are not San Francisco residents.

Exclusion criteria

* Cataract * Irregular corneal astigmatism (keratoconus) * Prior refractive surgery

Design outcomes

Primary

MeasureTime frameDescription
Cone spacing24 monthsThe current study will assess cone spacing twice at baseline and every 6 months for 30 months. The primary outcome will be measured at 24 months.

Secondary

MeasureTime frameDescription
Visual acuity24 monthsVisual acuity will be measured every 6 months for 30 months with the primary outcome measure at 24 months.

Countries

United States

Contacts

CONTACTJacque L. Duncan, M.D.
jacque.duncan@ucsf.edu415-514-4241
PRINCIPAL_INVESTIGATORJacque L. Duncan, M.D.

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026